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Abstract
Background: Chlamydia trachomatis (Ct) and Chlamydia pneumoniae (Cp) are medically significant
infectious agents associated with various chronic human pathologies. Nevertheless, specific roles
in disease progression or initiation are incompletely defined. Both pathogens infect established cell
lines in vitro and polymerase chain reaction (PCR) has detected Chlamydia DNA in various clinical
specimens as well as in normal donor peripheral blood monocytes (PBMC). However, Chlamydia
infection of other blood cell types, quantification of Chlamydia infected cells in peripheral blood and
transmission of this infection in vitro have not been examined.
Methods: Cp specific titers were assessed for sera from 459 normal human donor blood (NBD)
samples. Isolated white blood cells (WBC) were assayed by in vitro culture to evaluate infection
transmission of blood cell borne chlamydiae. Smears of fresh blood samples (FB) were dual
immunostained for microscopic identification of Chlamydia-infected cell types and aliquots also
assessed using Flow Cytometry (FC).
Results: ELISA demonstrated that 219 (47.7%) of the NBD samples exhibit elevated anti-Cp
antibody titers. Imunofluorescence microscopy of smears demonstrated 113 (24.6%) of samples
contained intracellular Chlamydia and monoclonals to specific CD markers showed that in vivo
infection of neutrophil and eosinophil/basophil cells as well as monocytes occurs. In vitro culture
established WBCs of 114 (24.8%) of the NBD samples harbored infectious chlamydiae, clinically a
potentially source of transmission, FC demonstrated both Chlamydia infected and uninfected cells
can be readily identified and quantified.
Conclusion: NBD can harbor infected neutrophils, eosinophil/basophils and monocytes. The
chlamydiae are infectious in vitro, and both total, and cell type specific Chlamydia  carriage is
quantifiable by FC.
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Background
Chlamydiae, obligate intracellular bacterial pathogens,
cause an array of medically and economically important
infectious diseases. Chlamydia trachomatis (Ct), the most
common cause of sexually transmitted bacterial disease, is
also the world's leading cause of infectious blindness [1].
Chlamydophila pneumoniae (Cp) is a ubiquitous respiratory
pathogen responsible for sinusitis, bronchitis, and 10–
15% of community acquired pneumonia cases world-
wide[2]. By age 20, ~50% of the population exhibits evi-
dence of past infection by C. pneumoniae and re-infection
is common throughout life [3]. Cp has attracted increasing
interest because it is associated with an array of chronic
human diseases that are not restricted to mucosal surfaces.
C. pneumoniae has been implicated in the pathobiology of
atherosclerosis [4-7] multiple sclerosis [8,9], Alzheimer's
disease (AD) [10], reactive arthritis [11], and asthma [12].
Although C. pneumoniae has been implicated as a factor in
this diverse array of chronic human diseases, it remains
unknown whether it is the causative agent or is simply
important in exacerbating these pathologies. By PCR, evi-
dence of these organisms has been found in the peripheral
blood mononuclear cells (PBMCs) of healthy blood
donors, and in patients with coronary artery disease [13-
16]. However, evidence of organism infectivity and infor-
mation outlining the intra-host spread of either organism
from an initial infection site in lung or genital tract to
widely disseminated sites where pathology occurs
remains to be fully defined. Using a rabbit model, and cell
culture, studies have shown that alveolar macrophages
serve as host cells for Cp [17], transporting it through the
mucosal barrier to the lymphatic system, then beyond
into the systemic circulation [18]. Chlamydia  infected
macrophages have been found in atherosclerotic plaques
[19], and recent studies have revealed that in vitro Cp can
infect human neutrophil granulocytes, and then initiate
delays in their spontaneous apoptosis [20]. Evidence has
been presented that in vitro Cp can infect B and T lym-
phocyte cell lines as well as human peripheral blood
mononuclear cells and induce a cytokine response
[21,22]. As demonstrated by PCR, Ct also disseminates
within the host following experimental genital tract infec-
tion in a murine model, but the mechanisms involved
have not yet been fully clarified [23-29].
We initiated an exploration of viable, infectious Chlamy-
dia carriage in human blood cells. The current study was
directed at assessing the prevalence of Chlamydia in sam-
ples from a Normal Blood Donor (NBD) population as
well as identifying the different types of white blood cells
that harbor this pathogen in vivo and quantifying their
numbers by flow cytometry. Results from our study exam-
ining a random cohort of 459 normal donor samples indi-
cated that (i) the average blood borne carriage rate of
Chlamydia for this cohort is 24.6%, (ii) Chlamydia can be
present in NBD peripheral blood granulocytic neutrophils
and eosinophil/basophil cells, as well as monocytes, (iii)
chlamydiae in 24.8% of NBD peripheral WBC are infec-
tious as demonstrated by in vitro culture and (iv) FC can
quantify both total infected cell load (ICL) and infected
cell type specific load (ICSL) in the peripheral WBC pop-
ulation.
Methods
Sample collection
Approval for using residual material from routinely col-
lected peripheral blood specimens from healthy normal
blood donors was obtained from the Institutional Review
Board at Baystate Medical Center. De-identified NBD
residuals collected in ethylenediaminetetraacetic acid
(EDTA) tubes were obtained from the Blood Bank at Bay-
state Medical Center in Springfield, MA from November
2001 to October 2002. Samples were collected monthly
and stored at 4°C until tested. For other assessments, de-
identified fresh blood sample residuals (FB), collected in
EDTA tubes, were obtained on a weekly basis from
patients seen at the University Health Services (UHS) and
used immediately. Unless otherwise specified, conjugated
secondary antibody reagents were obtained from Jackson
ImmunoResearch Laboratories, West Grove PA; the stand-
ard incubation was 1 h at room temperature (RT) unless
otherwise specified.
C. pneumoniae specific peptide ELISA
A 14 amino acid C. pneumoniae specific peptide sequence
deriving from the gene encoding the major outer mem-
brane porin protein of C. pneumoniae AR 39 [30] was syn-
thesized (Sigma Genosys, The Woodlands, TX). It served
as the antigen in ELISA tests for C. pneumoniae specific
antibody in NBD plasma samples. ELISA wells (NUNC™,
Nunc A/S, Roskilde, Denmark) were coated for 1 h with
100 ul containing 1 µg/ml peptide in phosphate buffered
saline pH 7.2 (PBS). Plasma samples were serially diluted
in ELISA wells using 0.1% BSA in PBS and standard proto-
cols for blocking (3% bovine serum albumin: BSA, Sigma,
St. Louis, MO), incubations, and washes (X3 with
0.1%BSA/PBS). Detection of bound human antibody
used alkaline phosphatase (AP)-conjugated goat anti-
human IgG and after 45 min incubation and multiple
rinses, 100 µl/well of P-Nitrophenyl Phosphate substrate
(pNPP, Sigma, St. Louis, MO) was added. Absorbances at
405 nm were measured with a VERSAmax Microplate
reader (Molecular Devices Sunny Vale, CA). Titers were
determined by comparison of absorbance readings of
known positive and negative controls with those of the
test samples.BMC Infectious Diseases 2006, 6:23 http://www.biomedcentral.com/1471-2334/6/23
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Immunostain of normal blood donor smears
Smears prepared with ~20 µl/ slide of whole blood col-
lected in EDTA were air dried then fixed 10 min in 70%
cold methanol (MEOH). Following PBS rinses, slides were
incubated in a moist chamber with a rabbit or guinea pig
anti-Chlamydia EB serum (Biomeda Corp. Foster City, CA)
then multiply rinsed in PBS. Bound anti-Chlamydia anti-
body was detected with fluoresein isothiocynate (FITC)-
conjugated goat anti-rabbit or donkey anti-guinea pig IgG.
Primary and secondary antibody incubations used the
standard protocol noted above. After PBS rinsing X3, cov-
erslips were mounted using Fluoromount G (BioWhit-
taker, Walkersville, MD), sealed, then examined and
photographed using a Nikon Eclipse E600 epifluores-
cence microscope and a SPOT digital camera (Digital
Instruments Inc.) or a Zeiss LSM 510 Meta Confocal Sys-
tem
Culture of normal blood donor samples
The buffy coat (BC) containing WBC, was removed from
each 5 ml NBD sample, rinsed X4 with sterile PBS, treated
to release EBs and cultured on J774A.1 monolayers as
described previously [30]. At 96 h post infection (pi)
monolayers on coverslips were rinsed with PBS, fixed with
70% MEOH, rinsed again and immunostained with a rab-
bit anti-Chlamydia EB, and then mounted as noted above.
Detection of Chlamydia infected Monocyte, Eosinophil/
Basophil and Neutrophil
Smears of BC cell pellets from each 5 ml fresh blood sam-
ples (FB), average donor age 28 years, were fixed with 70%
MEOH. Except as specified, immunostaining used rabbit
polyclonal anti-Chlamydia  EB antibody followed by a
TRITC conjugated goat anti-rabbit antibody. Specific cell
type detection used mouse monoclonals: anti-Human
CD14 (0.2 µg/106cells) (Sigma, Saint Louis, MO), or anti-
Human CD16b (1.0 µg/106cells) (BD Biosciences Phar-
migen, San Diego, CA.). Binding was detected with FITC-
conjugated goat anti-mouse IgG. For samples incubated
with PE-conjugated anti-Human CDw125 (1.0 µg/
106cells), bound anti-Chlamydia antibody detection used
FITC conjugated anti-rabbit antibody. Slides were incu-
bated, rinsed, mounted and sealed as described above and
digital images of optical sections through these samples
were acquired with a Zeiss LSM 510 Meta Confocal Sys-
tem.
Flow Cytometry assessment of a WBC dilution series
Flow cytometry (FC) quantification of Chlamydia-infected
peripheral blood WBC used PBS rinsed BC cells from
smear positive NBD samples. The WBC pool was fixed
and permeabilized (1% paraformaldehyde and 1% Triton
X-100, 10 min. at RT; Aldrich Chemical Company, Inc.,
Milwaukee, WI). PBS rinsed RBCs from the same samples
were also pooled. BC and RBC were separately incubated
with pre-diluted guinea pig anti-Chlamydia primary anti-
body followed by incubation with PE-conjugated F(ab')2
donkey anti-guinea pig IgG, PBS rinsed X3, and mono-dis-
persed using a nylon mesh filter (Lab-Line Instruments
Inc, Melrose Park, IL). A WBC dilution series was prepared
in separate tubes as follows: 100%, 90%, 80%, 70%, 60%,
50%, 40%, 30%, 20%, 10%, 5%, 2%, 1%, 0.5%, and 0%
WBC/tube. Sufficient RBCs were added to obtain a total of
50,000 cells/tube and the series analyzed by FACScan
(Becton, Dickinson and Company, Franklin Lakes, NJ).
Flow Cytometry of FB WBCs dual stained for Monocytes, 
Eosinophil/Basophil and Neutrophils
BC isolated from FB samples was pre-screened for Chlamy-
dia infected cells by anti-Chlamydia immunostaining as
described above. BC from four smear positive samples
and separately, BC from four smear negative samples were
pooled. Each pool was washed, fixed and permeabilized
as described above. After counting, aliquots of the cell
pools were incubated with the polyclonal guinea pig anti-
Chlamydia primary antibody and one of the three mono-
clonal antibodies, at the concentrations noted above. To
detect Chlamydia and CD14 or CD16b, BC were incubated
with PE-conjugated F(ab')2 donkey anti-guinea pig IgG
and FITC-conjugated rabbit anti-mouse IgG. Chlamydia in
BC immunostained with PE-conjugated anti-CDw125,
were detected with FITC conjugated F(ab')2 donkey anti-
guinea pig IgG. After standard incubations and rinsing,
samples were mono-dispersed, counted, diluted to obtain
1 × 106 cells/ml of sample and analyzed using the FACS-
can instrument.
Statistics
NBD sample data were analyzed using the SPSS® 11.5
graduate pack statistics program [SPSS, Inc., Chicago, IL].
Comparisons of culture and smear positivity used Cross-
tabs with the Fisher exact test to uncover nonrandom
associations between these two categorical variables and
Chi-Squared test and Kappa measure of agreement to
determine significance. To verify the reproducibility of
culture and smear assessments all samples were initially
tested in duplicate. Subsequently, approximately 20% of
the samples were re-tested by each method. The SD and
CV were calculated based on the differences in the positive
and negative percentages determined by the original vs.
the repeat tests. All tests were two sided, and the level of
significance was p ≤ 0.05.
Results
Preliminary observations of cells in blood smears of nor-
mal donor sample residuals and our studies of pediatric
blood sample residuals [30] showed each could contain
cells that were infected with Chlamydia. To screen normal
donors for Chlamydia carriage in circulating PBMCs, andBMC Infectious Diseases 2006, 6:23 http://www.biomedcentral.com/1471-2334/6/23
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to assess infectivity, we utilized ELISA, immunofluores-
cence microscopy, in vitro culture and flow cytometry
Presence of anti-C. pneumoniae antibody in NBD 
Samples
A random cohort of blood donor sample residuals was
obtained from the Blood Bank unit at Baystate Medical
Center over a 12 month period. Donor demographics are
presented in Table 1. As shown, the average age of this
cohort was 44 years and consisted of 55% male and 45%
female donors. Plasma was removed from the samples,
and an aliquot assayed by ELISA for anti-C. pneumoniae
antibody. As Table 2 shows, 219 (47.7%) of 459 samples
tested exhibited a positive titer against the 14 amino acid
C. pneumoniae-specific peptide. This level of sero-positive
status is fully consistent with published reports for this
age group and indicates this cohort is not anomalous in
this respect.
Microscopic demonstration of peripheral blood cells 
infected by Chlamydia
Samples, including blood, are routinely assessed for
Chlamydia by PCR and RT-PCR [5,13-15] but inherently
PCR cannot demonstrate whether this DNA represents
fragments or viable, infectious organisms [13-16] and
immunostaining to detect infected PBMCs is not routinely
used. This study therefore included immunofluorescent
staining as described above to identify Chlamydia-infected
NBD cells. As Figure 1A-C shows, Chlamydia  positive
material can be readily detected within lymphocyte-like
and monocyte-like cells and examination of all 459 sam-
ples demonstrated 113 (24.6%) were positive for Chlamy-
dia  within peripheral WBCs (Table 2). The blood
residuals, normally ≥30/month, were obtained over a 12
month period (Table 3) and comparison by month indi-
cated that samples collected in December exhibited dis-
tinctly higher carriage of intracellular Chlamydia: 42%
smear positive and 33% culture positive. In contrast, for
August and November carriage was notably lower. Culture
and smear positive results for these two months were
15%, 15% and 17%, 12% respectively. These divergent
percentages may reflect a variable carriage rate in this
cohort during the year since the sample numbers tested
for each of these months were similar: 34, 35 and 39,
respectively.
Demonstration in vitro of viable, infectious Chlamydia in 
WBC of peripheral blood samples
Immunostain for Chlamydia antigens demonstrated their
presence within PBMC. Therefore we next assessed
whether infectious organisms per se are present. Chlamy-
diae are known to infect macrophages in vivo [17-19] and
in vitro the J774A.1 macrophage monolayers are readily
infected by Chlamydia and support growth for ~120 h pi.
Using an effective culture method we developed previ-
ously and have described [30-33], WBC lysates were pre-
pared and tested in duplicate on J774A.1 monolayers. At
96 h pi the monolayers were rinsed, fixed, and immunos-
tained to detect Chlamydia. The results demonstrated that
of the 459 samples, 114 (24.8%) were positive for growth
of  Chlamydia  (Table 2). Figure 2 shows representative
immunostained monolayers incubated with WBC derived
inoculum from Chlamydia smear positive (Figure 2A) or
negative samples (Figure 2B). At 96 h pi the cultures of
smear positive samples contain large, late-stage inclusions
as well as small, newly forming inclusions and released
extracellular EBs. Table 2 shows that of the 459 samples
tested 76 were positive by both smear and culture tests. Of
the total positive samples, 37 were positive by smear but
negative for cultivable organisms, potentially an indicator
of persistence. Conversely 38 were negative by smear and
positive by culture; this last finding may reflect the small
sample size (20 µl) used in smear preparations. Together
however the smear and in vitro culture findings demon-
strated that not only do NBD samples carry PBMC
infected by Chlamydia and visually identifiable by fluores-
Table 1: Demographics: Random Blood Donor Cohort
Average Donor Age 44 years
Male 252 (55%)
Female 207 (45%)
Blood Type Distribution in Donor Cohort
A 40% B 10%
AB 4% O 46%
Table 2: Chlamydia Related Statistics: Normal Blood Donor Cohort
Assessment Positive Negative Total
Cp Serologic Status 219 (47.7%) 240(52.3%) 459
Smear Status 113 (24.6%) 346(75.4%) 459
Culture Status 114 (24.8%) 345(75.2%) 459
Culture and Smear Positive 76 (67.3% of total Smear Positive) N/A
Culture and Smear Negative 308 (89% of total Smear Negative) N/A
Culture Pos/Smear Negative 38 (33.3% of total Culture positive) N/A
Culture Neg/Smear Positive 37 (32.7%-of total Smear positive) N/ABMC Infectious Diseases 2006, 6:23 http://www.biomedcentral.com/1471-2334/6/23
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cent microscopy, but frequently these WBC borne chlamy-
diae are infectious.
Identification of Chlamydia infected Monocytes, 
Eosinophils/Basophils and Neutrophils in smears
Despite the demonstration of Chlamydia DNA in PBMC
samples, and demonstrations that in vitro numerous cell
lines can be infected by different Chlamydia species and
serovars, the specific types of WBC infected in vivo have
not been fully examined. We selected three specific CD
markers to identify WBC types and used them in conjunc-
tion with anti-Chlamydia antibody to immunostain WBCs
in peripheral blood sample residuals. Since WBC inher-
ently exhibit different life spans and can exhibit differen-
tial fragility, these assessments utilized fresh blood
sample residuals. Smears of these FB samples were pre-
pared, fixed and dual immunostained to detect Chlamydia
and either CD14 (monocytes), CDw125 (eosinophils/
basophils) or CD16b (neutrophil). Using Meta Confocal
microscopy, optical sections through cells were examined
and digital images acquired. Figure 3 shows representative
examples of Chlamydia-infected monocyte (CD14), eosi-
nophil/basophil (CDw125) and neutrophil (CD16b)
cells. These can exhibit punctate fluorescent staining (row
CD14 and CD125w) that reflects the expected uneven dis-
tribution of antigens. This is especially evident in non
adherent cells and readily detectible in an optical section
through a chlamydial inclusion. The anti-Chlamydia col-
umn shows the presence and distribution of Chlamydia
positive material within the individual optical section,
while the CD marker column identifies the cell type spe-
cific marker. The yellow or orange/yellow merge demon-
strates the co-localization of the immunoprobes in that
same optical section. The final column displays the DIC
images and shows the position and general morphology
of the individual cells. A comparison of the DIC and
Table 3: Sample Distribution: Normal Donor Cohort Positive by Month
Month 2001–2002 Sero-Positive Smear Positive Culture Positive
November 50 17 12
December 97 42 43
February 63 22 28
March 24 20 22
April 55 30 30
May 37 31 24
June 40 27 24
July 70 24 30
August 10 15 15
September 33 24 27
October 70 20 25
Immunostained smears of NBD whole blood samples Figure 1
Immunostained smears of NBD whole blood samples. Smears were prepared by standard methods, immunostained 
using an anti-Chlamydia EB antibody and an FITC-conjugated secondary antibody. Epifluorescence images in Panels A and B 
show representative examples of Chlamydia positive smears exhibiting characteristic inclusion bodies. Panel C shows a repre-
sentative smear negative sample and does not contain inclusion bodies or other Chlamydia positive material. Samples were pho-
tographed using a Nikon Eclipse E600 epifluorescence microscope and a SPOT digital camera. Original magnification 400×
A B CBMC Infectious Diseases 2006, 6:23 http://www.biomedcentral.com/1471-2334/6/23
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Merge images of the same row shows additional cells can
be present that are not immunostained by either antibody
(Figure 3-CD14 and CDw125). This observation serves to
indicate the specificity of the immunoprobes. Figure 4
presents merged images obtained at three different levels
from the same Z-axis optical sections through the cells
shown in Figure 3. As the optical sections in the CD16b
series show, the CD16b protein co-associates with the
chlamydial antigens (6 µ) but also is present at the cell
surface (10 µ).
Flow Cytometry of serially diluted buffy coat pool
Immunofluorescence allows detection of chlamydial anti-
gens by microscopy but smears are inherently susceptible
to significant sampling error. They also can not support
quantification of total Chlamydia infected cell numbers in
peripheral blood samples. We therefore utilized FC to
quantify potentially 'sticky' Chlamydia infected BC sam-
ples. After pooling WBC pre-screened by immunostain for
intracellular Chlamydia, a dilution series was prepared and
FACScan assessments for each dilution analyzed (Figure
5). The data shows the series is linear over a broad range
of infected cell numbers and that numeric differences
between dilutions in the series are readily evident. As Fig-
ure 5 also shows, even in the most dilute sample that con-
tains only 0.5% WBC, 3 ± 1.5 Chlamydia positive cells
above background were detectible in the 10,000 cell sam-
ple. In addition to indicating the utility of FC for detecting
Chlamydia  in peripheral WBC samples, the series also
serves as a control for subsequent FC directed towards
quantifying specific WBC types infected by Chlamydia in
vivo.
Presence of Chlamydia in Monocytes, Eosinophils/
Basophils and Neutrophils detected by Flow Cytometry
Given the demonstrated linearity and sensitivity, we uti-
lized dual channel FC as a rapid, sensitive tool to quantify
both the infected cell load (ICL) and the specific WBC
types infected in vivo. Using fresh blood samples, two
WBC pools were prepared and immunostained. One pool
contained WBC from samples positive by blood smear
anti-Chlamydia  immunostain examination. The second
pool, termed weakly positive, was prepared from samples
Chlamydia negative by immunostain but positive by initial
FC assessment. Aliquots of BC also were immunostained
with a single antibody and used to establish the appropri-
ate compensation for signal overlap between the two flu-
orescence channels and to establish appropriate,
conservative demarcations of fluorescence positive.
Peripheral WBC populations contain neutrophils
(CD16b), monocytes (CD14) and eosinophil/basophils
(CDw125) typically present at levels of 60–70%, 3–8%,
and 1–4% respectively. Aliquots of each WBC pool were
Chlamydiae within Peripheral Blood Transfer Infection when Cultured in vitro on J774A.1 host cell monolayers Figure 2
Chlamydiae within Peripheral Blood Transfer Infection when Cultured in vitro on J774A.1 host cell monolay-
ers. BC from NBD peripheral blood samples were isolated, lysed and layered onto host cell monolayers as described. Epifluo-
rescence images in Panel A show a representative example of a 96 h pi culture of a BC lysate from a Chlamydia smear positive 
sample and demonstrate these monolayers have remained healthy. Panel B shows a representative example of 96 h pi culture 
of a BC lysate from a Chlamydia negative smear sample. Note: panel A contains numerous cells with large inclusions, as well as 
cells with small inclusions and extracellular chlamydiae. These are characteristic of multiple replicative rounds in culture. Pho-
tographed using a Nikon Eclipse E600 epifluorescence microscope and a SPOT digital camera Original magnification 400×BMC Infectious Diseases 2006, 6:23 http://www.biomedcentral.com/1471-2334/6/23
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dual immunostained with anti-Chlamydia antibody and
monoclonal antibody specific for CD16b, CD14, or
CDw125 as described above. The dual channel FC data
(Figure 6) indicate that in the population of 10,000 cells
counted for the weakly positive pool, 10.4% were positive
for both Chlamydia and the neutrophil marker, CD16b,
while in the positive pool 7.4% exhibited dual positive
fluorescence. Notably, the dot plot for the positive pool
also contains a distinct distribution ('cloud') of cells lying
somewhat above the CD16b line of demarcation that
clearly is absent from the dot plot of the weakly positive
sample. In this 'cloud' region, numerous cells in the posi-
tive sample exhibit a lower level of CD16b expression, as
indicated by their location relative to the CD16b positive
demarcation line. This low CD16b expression level would
be consistent with the cells being immature neutrophils.
Dual immunostaining of Chlamydia-positive monocytes
(CD14) demonstrated that in the weakly positive pool,
2.3% of the 10,000 cells was dual positive, while in the
positive pool, 4.1% of cells, nearly double, was dual pos-
itive. Finally, in aliquots immunostained to detect
Chlamydia infected eosinophil/basophils (CDw125), dual
positives were identified in 1.9% of cells (weakly positive
sample) and 5.4% (positive sample), more than double
the number of cells.
This quantitative dual channel FC data indicates that in
vivo all three of these cell types can become infected, and
is consistent with our identification in dual immunos-
tained smears. The data also shows FC can quantify each
Infected and uninfected WBCs dual immunostained with CD Specific monoclonal and anti-Chlamydia antibody Figure 3
Infected and uninfected WBCs dual immunostained with CD Specific monoclonal and anti-Chlamydia anti-
body. Representative medial confocal microscopic images from the Z-axis series of optical sections through Chlamydia-infected 
human PBMC cells. Immunostaining used anti-Chlamydia EB antibody and either anti-CD14(monocyte), anti-CD 16b(neu-
trophil), or anti-CDw125 (eosinophil/basophil) mAb as indicated. Respectively, the Merge and DIC columns show the com-
bined FITC and TRITC images, and the distribution and morphology of the cells in the field. Note: In vivo each of the three cell 
types can be infected by Chlamydia and the CD14 row includes a Chlamydia infected cell (TRITC positive) that is not immunos-
tained by the ant-CD14 monoclonal (FITC negative).
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cell type and that both the dot plot patterns and cell type
specific numbers clearly differ for the weakly positive vs.
positive samples. Therefore even at the minimal level of
Chlamydia-infected cell carriage in these samples, cells of
each type become infected in vivo and both the total
infected cell load (ICL) and the infected cell type specific
load (ICSL) can be quantified.
Discussion
The studies presented here examined blood residuals
obtained throughout the year and provide an assessment
of blood cell borne Chlamydia carriage in a random cohort
of normal blood donors. The aims were to determine the
average rate of carriage, identify the key cell types infected
in vivo, test whether Chlamydia infected cells can transmit
infection to host cell monolayers, and assess quantifica-
Merged images at different depths from the confocal Z-axis series of dual immunostained WBCs Figure 4
Merged images at different depths from the confocal Z-axis series of dual immunostained WBCs. These merged 
TRITC-FITC confocal images are from different depths in the same series of Z-axis optical sections acquired for each of the 
cell types shown in Figure 3. The position of individual sections relative to the cell surface is indicated in µm below each image. 
Optical section images were acquired with the Zeiss Metaconfocal System.
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tion of the infected cell load in samples by using flow
cytometry.
Our serological results demonstrated that in this donor
population, 47.7% was sero-positive for C. pneumoniae.
Given the average age of 44 years, this finding is consistent
with the CDC report of serologic evidence of a previous
infection by C. pneumoniae by the age of 20 (50%) [3] and
demonstrates this donor cohort is not anomalous with
respect to sero-positivity. Our assessments also showed a
blood borne carriage rate for Chlamydia-infected cells of
24.6% positive. However, some notable differences were
observed in the rate of Chlamydia-infected WBC, depend-
ing on the time of year (Table 3). Although only a multi-
year study can verify seasonal variation, our finding
suggests that the season of collection could potentially be
a factor in the Chlamydia DNA detection rates of 18.5% to
46.15 % reported by others for PBMC. These PCR studies
have not concomitantly tested for infectious organisms,
nor is the time of year known [15,34-37]. Nevertheless,
given published reports, the carriage rate we observed was
not surprising, although the initial detection of blood
borne Chlamydia carriage in immunofluorescent stained
blood smears was unexpected. In addition, we also tested
WBC from these samples for infectious organisms using
an in vitro macrophage monolayer system, rather than the
non-phagocytic HEp-2 or HeLa cells often used by others.
As previously reported [30], this macrophage system is
readily phagocytic and thus will take up the rare chlamy-
dial EB in a more efficient manner. Moreover, using the
J774A.1 cell monolayers and IMEMZO, we routinely cul-
tured for 96 h pi, a time frame that supported re-infection
within the monolayers. As Figure 2 shows, these cells con-
tinue to look healthy and the amplification achieved at 96
h pi allowed rapid identification of samples with infec-
tious chlamydiae. Importantly, it also showed that the
Chlamydia in these NBD cells can be infectious (Table 2,
24.8%).
The presence and especially the infectivity of blood cell
borne chlamydiae is inherently relevant and potentially
significant in medical contexts as diverse as tissue and
organ transplantation [38,39], transfusion medicine and
blood banking. As demonstrated previously by PCR
[5,6,25,27] and here by immuno-detection and in vitro
culture of intracellular organisms per se, a level of carriage
clearly occurs. The demonstration that these organisms
can be infectious suggests that removal of WBC from
banked blood, for example, would be important and sim-
ple pre-storage leukoreduction is very effective [32]. In
addition, where possible an assessment of the infected cell
load in peripheral blood from an organ donor could be
highly relevant to transplant surgery.
Our data also shows that not all samples positive for
Chlamydia by examination of immunofluorescent smears
were positive for infectious Chlamydia by in vitro culture
(Table 2). This result may reflect the presence of persist-
ently infected cells. In vivo, this pathogen can enter a per-
sistent phase in response to various micro-environmental
conditions. In this state it would be detected in immun-
ofluorescent stained smears but produce few, if any infec-
tious EBs. Although reversion from this state has not been
directly demonstrated in vivo, studies have shown that in
vitro Chlamydia can revert and give rise to infectious EBs
[40-46]. Conversely, some immunostain negative sam-
ples were positive by culture. However, this result is not
surprising and likely reflects the 20 µl sample size used for
smear preparation vs. the much larger BC aliquot (50% of
the total BC isolated from a 5 ml whole blood sample)
used for the replicate in vitro cultures.
Recent experiments have shown in vitro infection of pri-
mary human neutrophils by Chlamydia as well as a con-
comitant delay of spontaneous apoptosis for infected
neutrophils but not uninfected ones [20]. In contrast, the
current study sought to identify blood borne WBC that
had become infected by Chlamydia in vivo. Both immun-
ofluorescence microscopy and flow cytometry demon-
strate additional infective capababilities for this stealth
pathogen. These studies used commercially available CD
specific monoclonal antibody and both techniques dem-
onstrated that non-clinical samples contain in vivo
FACScan Analysis of WBC Dilution Series from Donor  Peripheral Blood Immunostained for Chlamydia Figure 5
FACScan Analysis of WBC Dilution Series from 
Donor Peripheral Blood Immunostained for Chlamy-
dia. A buffy coat pool prepared from fresh human samples 
was assessed as positive for Chlamydia by immunostaining. 
The pool was immunostained for Chlamydia, serially diluted 
with RBCs pooled from the same samples then analyzed with 
a FACScan flow cytometer. The graphed results of the series 
demonstrates detection of Chlamydia infected cells in this 
non clinical down to 0.5% WBC/sample, a level of 3 ± 1.5 
infected cells in the total of 10,000 cells counted.
Infected WBC vs. Total WBC for 
Pooled NBD Samples
-2000
0
2000
4000
6000
8000
10000
12000
0 100 200 300 400 500
Infected WBC
T
o
t
a
l
 
W
B
CBMC Infectious Diseases 2006, 6:23 http://www.biomedcentral.com/1471-2334/6/23
Page 10 of 13
(page number not for citation purposes)
Detection, identification and quantification of Chlamydia infected cells in buffy coat pools from FB samples using flow cytometry Figure 6
Detection, identification and quantification of Chlamydia infected cells in buffy coat pools from FB samples 
using flow cytometry. Fresh blood smears were assessed for Chlamydia-positive cells by immunostain. Aliquots of the 
pooled BC were dual immunostained to detect intracellular Chlamydia and identify CD16b, CD14, or CDSw125 cells. For each 
of the dual-immunostained BC pairs, aliquots of 10,000 cells were assessed. Left panels: results for the weakly positive pool. 
Right panels: results for the positive pool. The dot plots indicate: in vivo each cell type can be infected with Chlamydia, the dif-
ferent cell-types exhibit different patterns with different percentages of Chlamydia-infected cells and inherently the same prepa-
ration provides enumeration of uninfected as well as infected cells, thereby providing numerical totals for infection of each cell 
type/10,000 cells.
     Weak Positive Pool                Positive Pool                    
                                                                                                      
 
 
C
D
 
1
6
b
C
D
 
1
4
 
 
 
 
 
 
 
 
 
 
 
C
D
w
1
2
5
1.3%                                     1.9%  8.2%                                     5.4% 
          2.3%   10.8%                                   4.1% 
10.4%      7.4%  30.3% 
42.0%          20.3%      5.7% 14.9% 
69.0% 
3.7% 
           18.1% 75.9%  56.4%                                  28.7% 
66.5%                                   19.9%  83.8%                                  13.0%BMC Infectious Diseases 2006, 6:23 http://www.biomedcentral.com/1471-2334/6/23
Page 11 of 13
(page number not for citation purposes)
infected neutrophils and eosinophil/basophil cells as well
as monocytes. PCR screening for Chlamydia of a portion of
these samples verified Chlamydia DNA is present and in
two instances where species specific primers were used, C.
trachomatis and C. pneumoniae were present in the same
sample (data not shown).
In terms of infected cell quantification, earlier studies had
applied FC in various contexts relating to Chlamydia e.g.
quantifying EB binding to standard host cell lines in vitro,
establishing Chlamydia sensitivity to antibiotics or exam-
ining the role of estrogen receptors in Chlamydia infec-
tions [47-51]. However quantification of peripheral WBC
infected in vivo by Chlamydia has not been reported, quite
likely because infected cell carriage in non-clinical blood
samples has been under appreciated. The FC quantifica-
tion of Chlamydia infected WBC (Figure 5) demonstrated
both sensitivity and linearity and provided a basis for the
cell type specific quantifications comparing weakly posi-
tive and positive samples shown in Figure 6. For neu-
trophils (CD16b+  cells) the FC data supports the
suggestion that unusual numbers of putatively immature
neutrophils may be present as a correlate of blood cell
borne Chlamydia carriage. FC dot plots also demonstrated
that the distribution patterns and the numbers of mono-
cytes and eosinophil/basophil cells are distinctly different
for these two pools. For the monocytes (CD14+ cells),
there were totals of 149,000 vs. 60,000 cells in the positive
vs. weakly positive pool and the detected level of Chlamy-
dia positive monocytes was 4.1% vs. 2.3%, a 1.8 fold dif-
ference. Interestingly, the total numbers of CDw125+,
eosinophil/basophil cells/10,000 cells was much higher
for the positive sample (1,360) vs. the weakly positive one
(320), a 4.25 fold difference, as was the percentage of each
pool that was infected (5.4% vs.1.9%), a 2.8 fold differ-
ence. After establishing parameters for routine use, a logi-
cal next step would be to assess WBC from patient
samples and focus on clinical conditions in which a
Chlamydia involvement is known or suspected.
Our evidence from the blood smear studies, as well as the
earlier PCR data of others that indicated Chlamydia DNA
carriage in normal populations, underscore the potential
relevance of these and additional FC quantification stud-
ies. The demonstration that these chlamydiae can be
infectious has implications for specific diagnoses, as well
as health care in general. Clearly even low carriage levels
of Chlamydia-infected cells can be quantified by FC (Fig-
ure 5) supporting determination of the total infected cell
load in the peripheral circulation. Additionally, the FC
dual immunostain data (Figure 6) shows that for specific
cell types, both the total and infected cell populations are
readily and simultaneously quantifiable. Such informa-
tion would support establishing individual cell type spe-
cific load and potentially identify any skewing of infected
cell types that might be associated with parameters such as
levels of Chlamydia-infected WBC carriage or specific clin-
ical presentations.
The significance of these specific findings and dot plot
patterns remain to be established and will require addi-
tional broad based assessments. However, FC already is a
routine diagnostic tool employed to enumerate CD4+ T
cells and CD34+ progenitor cells and to screen for HLA-
B27 antigen and leukemia/lymphoma immuno-pheno-
typing [52]. Thus once optimized for this application, FC
could be routinely available to provide a non-invasive
means of detecting and monitoring WBC infection by
Chlamydia and could be of considerable diagnostic and
prognostic value as well as a screening tool to for routine
health assessments.
Conclusion
Within the normal blood donor population tested, there
is a Chlamydia carriage rate of 24.6%, contained in the
WBC of the peripheral circulation. As demonstrated by
fluorescent immunostaining combined with confocal
microscopy and flow cytometric techniques, this patho-
gen is present within neutrophils and eosinophil/
basophil cells, as well as in the monocyte/macrophage
cells previously implicated. In addition, in vitro culture
demonstrated Chlamydia in lysates of these non-clinical
peripheral WBC can be infectious and readily transmits
the Chlamydia to host cell monolayers. Therefore carriage
of Chlamydia in the peripheral circulations could be signif-
icant in the context of transfusion or transplant recipients
as well as routine health assessments.
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